Ulcerative colitis Biologics
Conditions
Interventions
Infliximab:Infliximab (5 mg / kg / body weight) is infused intravenously at 0, 2, 6, 14, and 22 weeks.
Vedolizumab:Intravenous infusion of vedolizumab 300 mg at 0, 2, 6, 14, and 22 weeks
Ustekinumab:
Sponsors
Naganuma Makoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who meet the criteria of the ulcerative colitis diagnostic criteria (revised in 2018) of the Ministry of Health, Labor and Welfare Specified Disease or Intractable Inflammatory Intestinal Disorders Research Group 2) Patients with steroid resistance / dependence at the time of registration or who have previously received systemic steroids 3) Patients who have never used antiTNFa antibody preparations, ustekinumab, or vedolizumab 4) Patients with a Mayo score of 6 points or higher and an endoscopic Mayo score of 2 or higher at the time of registration (Endoscopic scores at the enrollment were assessed by local institutional endoscopists) 5) Patients who are 16 years of age or older at the time of obtaining consent and who have obtained written consent from the patient. For patients with age of 16-19, patients who have obtained the written consent of the person and the substitute 6) Those who have received sufficient explanation before participating in this study, and who have obtained the document for contents after sufficient explanations. For minors, those who have obtained the written consent of the person and the substitute Definition of steroid resistance The failure to respond to systemic steroid treatment at a dose of 1 to 1.5mg per kg per day for 1 week. Definition of steroid dependence Either an inability to reduce steroids below the equivalent dose of prednisolone 10 mg per day within 3 months of starting steroid therapy without recurrent active disease, or relapse within 3 months of cessation of steroid therapy.
Exclusion criteria
Exclusion criteria: 1) Patients classified as fulminant in the clinical severity classification 2) Patients who are suspected of having colitis rather than ulcerative colitis (infectious enteritis, etc.) 3) Patients with symptomatic gastrointestinal stricture 4) Patients who areplanning colectomy for UC 5) Pregnant women or patients who may be pregnant, lactating patients or those who wish to become pregnant during the study period 6) Patients with contraindications to use infliximab, ustekinumab, or vedolizumab in the package insert 7) Patients who the doctor in charge deems inappropriate to be included in this study 8) Patients participating in clinical trials of other medications 9) Excluding criteria for concomitant medication as below; 1 Patients who have increased the dose of oral 5-aminosalicylic acid within 2 weeks before the registration. 2 Patients who have newly started the enema or suppository treatment with 5-aminosalicylic acid or steroids within 1 week before the registration. 3 Patients receiving oral prednisolone (or equivalent corticosteroid) or intravenous corticosteroid in excess of 30 mg /day within 2 weeks before the registration. In addition, patients who are receiving 30mg daily dose or less of oral or intravenous corticosteroids and whose dosage is not constant within 2 weeks. 4 Patients who newly started thiopurine (azathioprine / 6-mercaptopurine) within 8 weeks before the registration. Patients whose dose of thiopurine was changed within 2 weeks before registration in patients who already received thiopurine. 5 Patients receiving cyclosporine or tacrolimus within 4 weeks before the registration. 6 Patients receiving carotegrastmethyl,upadacitinib,filgotinib or tofacitinib within a week before the registration. 7 Patients receiving apheresis therapy within 4 weeks before the registration. tofacitinib
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission rate at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Clinical response rate at Week 12 2 Endoscopic remission rate at Week 12 3 Complete endoscopic remission at Week12 4 Histological remission at Week 12 5 The rate of fecal calprotectin level less than 150ng/g at Week 12 6 Clinical remission rate at Week 2 7 The rate of no appearance of blood in stool at Week 12 8 Significance of Patients report outcome from Week 0 to Week 2 and Week 12 9 Significance of Mayo subscore (blood in stool) from Week 0 to Week 2 and Week 12 10 Significance of Mayo subscore (number of daily stool) from Week 0 to Week 2 and Week 12 11 Significance of Mayo endoscopic subscore from Week 0 to Week 12 12 Significance of fecal calprotectin level from Week 0 to Week 12 | — |
Contacts
Public ContactMakoto Naganuma
Kansai Medical University Hospital
Outcome results
None listed